price usd
ahead next tuesday result examin august/septemb us sale trend
use proprietari db med-tech databas glean insight trend
key product across mdt portfolio remind get data day
month end due time mdt earn releas
month data avail prior print
use db med-tech databas model allow us track us
world-wide compani sale two month data made
model adjust across mdt segment includ
put take net chang total sale forecast immateri
top line temper cvg growth forecast
owe myriad persist near-term challeng data show continu
weigh segment perform quarter lvad icd/crt-d coronari stent
dcb partial offset headwind strength tavr continu
micra-driven share captur pacemak thu think cvg sale could come
somewhat short consensu guidanc
mitg updat growth forecast likewis put us
consensu guidanc resolut
supplier steril issu weigh lead better perform-
tialli
convers rtg estim move higher put us
street compani guidanc reflect improv trend
spine like driven combin new product better salesforc product
mazor final begin yield improv trend core implant favor db
sale data likewis prompt us nudg estim specialti therapi higher
diabet growth estim unchang line con-
sensu manag lsd guid busi dont sale data
net result model revis lower total compani revenu estim
immateri keep us right line consensu per
guidanc oper margin gain minim owe fx invest-
deutsch bank seek busi compani cover research report thu investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis disclosur analyst certif locat
distribut gmt
ment support sever new product introduct model ebit margin
tad better versu year ago line street ep
equal consensu line guidanc rang
net-net maintain buy rate due decent revenu growth
driven sever segment lower valuat rel large-cap
med-tech name increas evid recoveri spine
headwind year busi inde transit headwind tail-
wind spine could drive addit oper leverag due outsiz profitabil-
iti robust pipelin next year includ transcathet valv surgi-
cal robot diabet potenti earn upsid next month
addit tax save think potenti tune bp
made sever chang revenu model driven db us med-tech databas figur august/septemb net
result modest decreas total sale estim right line street
 model unchang ep remain equal consensu consist guidanc
us sale data august/septemb point crhf segment perform trend prior forecast
due princip persist pressur icd continu lvad challeng
anniversari though pacemak appear improv bit sequenti
result weve lower us crhf growth estim versu previous
august/septemb figur db us med-tech databas histor captur us sale point
continu weak mdt icd/crt-d franchis compani continu under-perform overal market owe
unfavor replac cycl headwind particularli within heart
failur categori unfavor product cycl dynam
differenti competitor devic notabl boston emblem s-icd heartlog hf diagnost technolog continu take share
bright side data indic mdt crt-d busi final begin show sign stabil replac cycl
headwind result launch new devic longer batteri life year ago start abat consist
manag commentari tct late septemb compani note crt-d gener replac market
becom net neutral us tachi perform
mdt implant busi fare significantli better pacemak versu icd past year thank mainli
continu uptak highli differenti micra leadless transcathet pacer lesser extent good uptak azur famili
pacemak estim account well north transven pacer implant
db sale data septemb point us bradi growth improv modestli versu
said dataset show clear slowdown mdt us pacer busi past coupl quarter think like reflect
penetr micra within current indic patient popul start plateau recal current micra vr iter limit
singl chamber categori util patient av block concomit af thu cap address market
bradi patient present
howev next gener micra av also util patient av block normal atrial function thu tripl
address market estim overal patient popul indic perman pacemak launch micra av
expect result reacceler mdt pacemak franchis
per us sale dataset tyrx sale growth remain strong post wrap-it data readout march demonstr highli
compel valu proposit proprietari offer reduct major infect includ fewer pocket infect post
icd/pacemak implant penalti vi -- vi procedur time advers event
data show tyrx price hold steadi rang
technolog adopt still rel modest continu think tyrx could ultim becom substanti revenu contributor
mdt franchis next year anti-infect envelop use non-mdt implant also
collater uplift compani devic similar weve seen linq cardiac monitor implant past
within csh divis august/septemb us sale data signal meaning sequenti acceler reflect continu strength
tavr offset coronari stent market remain challeng consist edward result
compani report robust us sapien growth clinician check earlier week confirm tavr market growth remain
robust aftermath low-risk data earlier year
recent convers industri contact indic increment worsen de price trend light biotronik on-going launch
orsiro drug-elut stent biotronik aggress price make inroad market long domin
incumb turn forc make asp concess notabl even biotronik sever month us
launch dataset hasnt yet captur singl sale transact septemb like indic minim traction particularli given
sale captur us de market fairli robust simpli fact hospit contract high-volum devic take
time suspect combin
light latest sale data up us csh growth estim versu previous
db sale data august septemb confirm dcb util remain pressur light linger safeti concern post meta-
analysi public late last year figur indic sale yr/yr sale declin around recent month mdt admir
bdx lutonix corrobor commentari bdx call last week
albeit clearli still challeng data show stabil admir volum recent month lutonix may yet
bottom magnitud monthli yr/yr declin steadili increas sinc juli appear gain sever point
us dcb share late share roughli equal within market sampl despit broader fda label lutonix includ
expect secur approv
avf come month million opportun mostli us coupl
anniversari fda march physician advisori yield improv dcb trend philips/spectranet stellarex
remain distant third
also note call remain dialogu fda regard regulatori prospect lutonix btk indic
develop clear implic mdt admir
august/septemb us sale data signal sequenti better perform spine healthier trend rel
prior think like reflect uptak new product better salesforc product uplift core implant sale
mazor final start bear fruit
accordingli boost us spine forecast versu previous
rtg brain therapi specialti therapi
db data septemb point sequenti slower brain therapi growth consist
model accordingli keep us ww growth estim intact also note
remark call last week us stroke market slow recent month impli slower
within specialti therapi trend seen dataset prompt us rais revenu forecast
million model sequenti better us ww growth note axon recent
announc
sacral nerv stimul system compet
medtron interstim heretofor competit axon launch wont impact result
manag commentari around interstim pipelin recharg system particular interest
initi commerci
launch
mitg db data august/septemb signal sequenti slower growth even despit resolut supplier
steril yield better result surgic innov look off-set slower growth
sequenti
